The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
The registered capital of the newly founded company is € 50 million
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The new campus has been designed as an employee-centred experience and ecosystem zone
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Subscribe To Our Newsletter & Stay Updated
